PDF(Pubmed)
Abstract：
Trophoblast cell surface antigen 2 (Trop2) is overexpressed in a range of solid tumors and participants in multiple oncogenic signaling pathways, making it an attractive therapeutic target. In the past decade, the rapid development of various Trop2-targeted therapies, notably marked by the advent of the antibody-drug conjugate (ADC), revolutionized the outcome for patients facing Trop2-positive tumors with limited treatment opinions, such as triple-negative breast cancer (TNBC). This review provides a comprehensive summary of advances in Trop2-targeted therapies, including ADCs, antibodies, multispecific agents, immunotherapy, cancer vaccines, and small molecular inhibitors, along with in-depth discussions on their designs, mechanisms of action (MOAs), and limitations. Additionally, we emphasize the clinical research progress of these emerging Trop2-targeted agents, focusing on their clinical application and therapeutic efficacy against tumors. Furthermore, we propose directions for future research, such as enhancing our understanding of Trop2\'s structure and biology, exploring the best combination strategies, and tailoring precision treatment based on Trop2 testing methodologies.
摘要：
滋养层细胞表面抗原2（Trop2）在一系列实体瘤和多个致癌信号通路的参与者中过度表达，使其成为有吸引力的治疗靶点。在过去的十年里,各种Trop2靶向疗法的快速发展，特别是以抗体-药物偶联物（ADC）的出现为标志，彻底改变了治疗意见有限的Trop2阳性肿瘤患者的结果，例如三阴性乳腺癌（TNBC）。这篇综述全面总结了Trop2靶向治疗的进展，包括ADC,抗体，多特异性药物，免疫疗法，癌症疫苗,和小分子抑制剂，随着对他们设计的深入讨论，行动机制（MOA），和限制。此外,我们强调了这些新兴的Trop2靶向药物的临床研究进展，重点关注其临床应用和对肿瘤的治疗效果。此外，我们提出了未来研究的方向，例如加强我们对Trop2的结构和生物学的理解，探索最佳组合策略，并根据Trop2测试方法定制精确处理。
